阿尔茨海默病的临床诊治进展
网络出版日期: 2022-02-25
基金资助
上海交通大学医学院高峰高原计划——“研究型医师”(2017);科技部“脑科学与类脑研究”重大课题(2021ZD0201804)
李建平, 任汝静, 王刚 . 阿尔茨海默病的临床诊治进展[J]. 诊断学理论与实践, 2022 , 21(01) : 18 -21 . DOI: 10.16150/j.1671-2870.2022.01.005
| [1] | Winkler AS. The growing burden of neurological disorders in low-income and middle-income countries: priorities for policy making[J]. Lancet Neurol, 2020, 19(3):200-202. |
| [2] | Jia J, Wei C, Chen S, et al. The cost of Alzheimer′s disease in China and re-estimation of costs worldwide[J]. Alzheimers Dement, 2018, 14(4):483-491. |
| [3] | Yu X, Chen S, Chen X, et al. Clinical management and associated costs for moderate and severe Alzheimer′s disease in urban China: a Delphi panel study[J]. Transl Neurodegener, 2015, 4:15. |
| [4] | Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer′s disease[J]. Alzheimers Dement, 2018, 14(4):535-562. |
| [5] | Hampel H, Cummings J, Blennow K, et al. Developing the ATX(N) classification for use across the Alzheimer disease continuum[J]. Nat Rev Neurol, 2021 Sep, 17(9):580-589. |
| [6] | Hansson O, Seibyl J, Stomrud E, et al. CSF biomarkers of Alzheimer′s disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts[J]. Alzheimers Dement, 2018, 14(11):1470-1481. |
| [7] | Oh ES, Troncoso JC, Fangmark Tucker SM. Maximizing the potential of plasma amyloid-beta as a diagnostic biomarker for Alzheimer′s disease[J]. Neuromolecular Med, 2008, 10(3):195-207. |
| [8] | Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders[J]. JAMA, 2020, 324(8):772-781. |
| [9] | Moscoso A, Grothe MJ, Ashton NJ, et al. Time course of phosphorylated-tau181 in blood across the Alzheimer′s disease spectrum[J]. Brain, 2021, 144(1):325-339. |
| [10] | Jia L, Qiu Q, Zhang H, et al. Concordance between the assessment of Aβ42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid[J]. Alzheimers Dement, 2019, 15(8):1071-1080. |
| [11] | Jia L, Zhu M, Kong C, et al. Blood neuro-exosomal synaptic proteins predict Alzheimer′s disease at the asymptomatic stage[J]. Alzheimers Dement, 2021, 17(1):49-60. |
| [12] | Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer′s disease[J]. Alzheimers Dement, 2018, 14(4):535-562. |
| [13] | Ma Y, Zhang S, Li J, et al. Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow-up: a meta-analysis[Corrected][J]. Medicine (Baltimore), 2014, 93(27):e150. |
| [14] | Lohith TG, Bennacef I, Vandenberghe R, et al. Brain imaging of alzheimer dementia patients and elderly controls with 18 F-MK-6240, a PET tracer targeting neurofibrillary tangles[J]. J Nucl Med, 2019, 60(1):107-114. |
| [15] | Chandra A, Valkimadi PE, Pagano G, et al. Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer′s disease and mild cognitive impairment[J]. Hum Brain Mapp, 2019, 40(18):5424-5442. |
| [16] | Iaccarino HF, Singer AC, Martorell AJ, et al. Gamma frequency entrainment attenuates amyloid load and modifies microglia[J]. Nature, 2016, 540(7632):230-235. |
| [17] | Martorell AJ, Paulson AL, Suk HJ, et al. Multi-sensory Gamma stimulation ameliorates Alzheimer′s-associated pathology and improves cognition[J]. Cell, 2019, 177(2):256-271,e22. |
| [18] | Patnode CD, Perdue LA, Rossom RC, et al. Screening for cognitive impairment in older adults: updated evidence report and systematic review for the US preventive services task force[J]. JAMA, 2020, 323(8):764-785. |
| [19] | 2020 Alzheimer′s disease facts and figures[J/OL]. Alzheimers Dement, 2020-03-10) [2022-10-10]. https://pubmed.ncbi.nlm.nih.gov/32157811/. |
| [20] | Wang X, Sun G, Feng T, et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer′s disease progression[J]. Cell Res, 2019, 29(10):787-803. |
| [21] | Xiao S, Chan P, Wang T, et al. A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer′s dementia[J]. Alzheimers Res Ther, 2021, 13(1):62. |
| [22] | Wang T, Kuang W, Chen W, et al. A phase II randomized trial of sodium oligomannate in Alzheimer′s dementia[J]. Alzheimers Res Ther, 2020, 12(1):110. |
| [23] | Novak P, Schmidt R, Kontsekova E, et al. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer′s disease: a randomised, double-blind, placebo-controlled, phase 1 trial[J]. Lancet Neurol, 2017, 16(2):123-134. |
| [24] | Panza F, Solfrizzi V, Seripa D, et al. Tau-based therapeutics for Alzheimer′s disease: active and passive immunotherapy[J]. Immunotherapy, 2016, 8(9):1119-1134. |
| [25] | Höglinger GU, Litvan I, Mendonca N, et al. Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial[J]. Lancet Neurol, 2021, 20(3):182-192. |
| [26] | Nature Cell Started Commercial Clinical Trials Phase I And II "ASTROSTEM," Stem Cell Drug For Alzheimer′s Disease Treatment In U.S.[Z]. |
| [27] | Winblad B, Graf A, Riviere ME, et al. Active immunotherapy options for Alzheimer′s disease[J]. Alzhe-imers Res Ther, 2014, 6(1):7. |
| [28] | Sumner IL, Edwards RA, Asuni AA, et al. Antibody Engineering for Optimized Immunotherapy in Alzheimer′s Disease[J]. Front Neurosci, 2018, 12:254. |
| [29] | Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer′s disease with lecanemab, an anti-Aβ protofibril antibody[J]. Alzheimers Res Ther, 2021, 13(1):80. |
/
| 〈 |
|
〉 |
